Figure 2
Cumulative incidence of acute myeloid leukemia (AML) progression in lenalidomide-treated vs untreated patients. Analysis performed with mortality as the competing risk and with left truncation.
Figure 2 | Leukemia
Cumulative incidence of acute myeloid leukemia (AML) progression in lenalidomide-treated vs untreated patients. Analysis performed with mortality as the competing risk and with left truncation.
